These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29308691)

  • 1. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.
    Lendvai N; Tsakos I; Devlin SM; Schaffer WL; Hassoun H; Lesokhin AM; Landau H; Korde N; Mailankody S; Smith E; Chung DJ; Koehne G; Shah GL; Alexander A; Patel M; Ballagi A; Grundberg I; Giralt SA; Landgren O
    Leuk Lymphoma; 2018 Aug; 59(8):1981-1985. PubMed ID: 29308691
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of Carfilzomib-Associated Cardiac Adverse Events.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
    Shah C; Bishnoi R; Jain A; Bejjanki H; Xiong S; Wang Y; Zou F; Moreb JS
    Leuk Lymphoma; 2018 Nov; 59(11):2557-2569. PubMed ID: 29465266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature.
    Serra W; Fantin A; Longo C; Rabia G; De Rosa F; Plenteda C; Re F; Crisafulli E; Chetta A
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(3):253-258. PubMed ID: 30516116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity with carfilzomib at doses greater than 27 mg/m
    Kim GY; Ahuja T; Papadopoulos J; Cirrone F
    J Oncol Pharm Pract; 2019 Jan; 25(1):229-233. PubMed ID: 28914153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose carfilzomib proteasome inhibition induces anemia by oxidative hemolysis: A case series of 8 patients from a single centre.
    Rajagopal R; Bennett R; Liang J; Royle G
    Am J Hematol; 2019 Aug; 94(8):E215-E216. PubMed ID: 31066096
    [No Abstract]   [Full Text] [Related]  

  • 8. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
    Tjionas H; Gupta AK
    J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
    Patel VG; Cornell RF
    Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
    Bishnoi R; Xie Z; Shah C; Bian J; Murthy HS; Wingard JR; Farhadfar N
    Cancer Med; 2021 Jan; 10(1):70-78. PubMed ID: 33169938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
    Mian HS; Fiala MA; Sanchez L; Vij R; Wildes TM
    Ann Hematol; 2021 May; 100(5):1261-1266. PubMed ID: 33475778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
    Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
    J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
    Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
    Shen X; Wu C; Lei M; Yan Q; Zhang H; Zhang L; Wang X; Yang Y; Li J; Zhu Y; Chen L
    Cell Death Dis; 2021 Apr; 12(5):429. PubMed ID: 33931582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
    Cole DC; Frishman WH
    Cardiol Rev; 2018; 26(3):122-129. PubMed ID: 29077585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
    Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
    J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.